A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

Inclusion Criteria Patients must have: Asymptomatic or minimally symptomatic HIV infection (no evidence of AIDS). CD4 count <= 400 cells/mm3 within 6 weeks prior to study entry (CD4 count changed to 100 - 400 cells/mm3 per amendment). Tolerated the current nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known hypersensitivity to thymopentin or any component of the formulation. Significant chronic underlying medical illness that would impede study participation. Grade 2 or higher peripheral neuropathy related to nucleoside analog antiretroviral treatment. Concurrent Medication: Excluded: Any antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine. HIV vaccines or any investigational or non-FDA approved medication or immunomodulatory or experimental therapy within 30 days prior to study entry. Patients with the following prior condition are excluded: Abnormal chest x-ray consistent with active opportunistic infection within 6 weeks prior to study entry. Prior Medication: Excluded: Any prior antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine within 30 days prior to study entry. Required: Current nucleoside analog antiretroviral treatment. Required: Nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry. Significant active alcohol or drug abuse sufficient to prevent study compliance.